Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Affimed $115 million offering of shares
We advised the underwriters on the public equity offering
REGENXBIO $230.3 million stock offering
We advised the underwriters on a public equity offering
Generation Bio $225.4 million stock offering
We advised the underwriters on the public equity offering
NeoGenomics $230 million stock and $345 million convertible notes offerings
We advised the joint book-running managers on the public offerings of stock and convertible notes
Gracell Biotechnologies $209 million IPO and Nasdaq listing
We advised the underwriters on the IPO of ADSs
NGM Biopharmaceuticals $125 million follow-on offering
We advised the joint book-running managers on the public equity offering
Gamida Cell $75 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $75 million SEC-registered follow-on…
ImmunityBio merger with NantKwest
Davis Polk is advising Goldman Sachs & Co. LLC and Lazard Frères & Co. LLC as financial advisers to ImmunityBio, Inc…
Solid Biosciences $90 million common stock PIPE offering
Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Solid…
Atara Biotherapeutics $175 million common stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a…